Susquehanna International Group, LLP Cure Vac N.V. Call Options Transaction History

Susquehanna International Group, LLP

14 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$2.74 - $3.79 $106,860 - $147,810	39,000 Added 42.53%	130,700 $384,000
Q2 2024 Aug 15, 2024	BUY	$2.31 - $4.99 $211,827 - $457,583	91,700 New	91,700 $311,000
Q2 2023 Aug 11, 2023	SELL	$6.69 - $12.25 $177,285 - $324,625	-26,500 Reduced 37.48%	44,200 $460,000
Q1 2023 May 16, 2023	SELL	$6.38 - $12.5 $318,362 - $623,750	-49,900 Reduced 41.38%	70,700 $492,000
Q4 2022 Feb 14, 2023	BUY	$5.75 - $8.5 $26,450 - $39,100	4,600 Added 3.97%	120,600 $727,000
Q3 2022 Nov 14, 2022	SELL	$7.48 - $15.24 $617,848 - $1.26 Million	-82,600 Reduced 41.59%	116,000 $914,000
Q2 2022 Aug 15, 2022	BUY	$13.18 - $19.41 $1.02 Million - $1.5 Million	77,200 Added 63.59%	198,600 $2.7 Million
Q1 2022 May 16, 2022	SELL	$14.73 - $35.25 $930,936 - $2.23 Million	-63,200 Reduced 34.24%	121,400 $2.38 Million
Q4 2021 Feb 14, 2022	SELL	$33.72 - $48.22 $647,424 - $925,824	-19,200 Reduced 9.42%	184,600 $6.33 Million
Q3 2021 Nov 15, 2021	SELL	$49.26 - $74.5 $43.8 Million - $66.2 Million	-889,000 Reduced 81.35%	203,800 $11.1 Million
Q2 2021 Aug 11, 2021	BUY	$56.91 - $127.53 $44.1 Million - $98.8 Million	774,500 Added 243.32%	1,092,800 $80.3 Million
Q1 2021 May 17, 2021	BUY	$79.79 - $126.29 $15.1 Million - $23.8 Million	188,700 Added 145.6%	318,300 $29.1 Million
Q4 2020 Feb 16, 2021	SELL	$46.76 - $136.27 $3.77 Million - $11 Million	-80,600 Reduced 38.34%	129,600 $10.5 Million
Q3 2020 Nov 16, 2020	BUY	$43.8 - $77.2 $9.21 Million - $16.2 Million	210,200 New	210,200 $9.79 Million

12.3M

164K

117K

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $553M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.